Hypofractionated accelerated Radiotherapy versus Conventional Radiotherapy in Glioblastoma Multiforme: A prospective randomised controlled study

This is a prospective, open label randomised controlled study comparing the safety and efficacy of Hypofractionated accelerated Radiotherapy at 52.5 Grey in 15 fractions with Conventional Radiotherapy at 60 Grey in 30 fractions, both administered with concurrent temozolomide @ 75 mg/m2 once daily throughout radiotherapy and six cycles of adjuvant temozolomide @ 150-200 mg/m2 starting 4 weeks after Radiotherapy, administered once daily for 5 days and each cycle delivered at an interval of 4 weeks in 52 patients of Glioblastoma Multiforme. The study is single institutional which aims to assess loco-regional control as primary outcome and overall survival, progression free survival and Quality of life as secondary oiutcomes.